Salk Institute scientists discovered that bile acids in the liver can weaken immune cell function, making immunotherapy less effective against liver cancer. They pinpointed specific bile acids that ...

Dr. Anjana Pillai explains that staging liver cancer involves assessing tumor size, spread, and vessel involvement to guide treatment. Dr. Anjana Pillai, professor of medicine, as well as surgery, and ...

Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat and cardiovascular risks in MASLD models. The drug duo works better together ...

A multidisciplinary team from China performed the world’s first successful genetically modified pig auxiliary liver xenotransplant in a living human. The liver was able to function and support the ...

BraDiPho (Brain Dissection Photogrammetry) is an innovative tool for the study of white matter connections in the human brain ...

A 2D mammogram is the conventional way to look at breast tissue. The machine takes 2 x-ray pictures of each breast. One is ...

Share on Pinterest Could a heart drug combo help reverse fatty liver disease? Image credit: Maskot/Getty Images Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company's drug for ...

The published paper reports on the results of more than 5 years of collaboration and introduces a new instrument that the ...

Grey’s Anatomy wants you to answer one question: how far would you go to save your own child? How much is a risk worth taking to save their life? I think a lot of parents are going to admit that risks ...

Television ‘It Was Challenging For Me’: Grey’s Anatomy Star Gets Real About Working With Ellen Pompeo On Big Surgery Scene Television I’ve Been Wondering If Grey’s Anatomy Will Bring Piper Perabo Back ...

The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in hepatocellular carcinoma patients. Median progression-free survival was 8.3 months with ...